nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimethoprim—DHFR—bone cancer	0.524	0.859	CbGaD
Trimethoprim—DHFR—Methotrexate—bone cancer	0.154	0.499	CbGbCtD
Trimethoprim—TYMS—Methotrexate—bone cancer	0.108	0.347	CbGbCtD
Trimethoprim—CYP3A4—bone cancer	0.0857	0.141	CbGaD
Trimethoprim—CYP2C9—Cisplatin—bone cancer	0.0131	0.0423	CbGbCtD
Trimethoprim—ABCB1—Cisplatin—bone cancer	0.0127	0.0411	CbGbCtD
Trimethoprim—ABCB1—Doxorubicin—bone cancer	0.00853	0.0275	CbGbCtD
Trimethoprim—ABCB1—Methotrexate—bone cancer	0.00826	0.0267	CbGbCtD
Trimethoprim—Trimetrexate—DHFR—bone cancer	0.00538	1	CrCbGaD
Trimethoprim—CYP3A4—Doxorubicin—bone cancer	0.00511	0.0165	CbGbCtD
Trimethoprim—TYMS—Pyrimidine metabolism—NT5C3A—bone cancer	0.00237	0.0734	CbGpPWpGaD
Trimethoprim—DHFR—Folate Metabolism—FOLR1—bone cancer	0.00179	0.0554	CbGpPWpGaD
Trimethoprim—TYMS—G1/S-Specific Transcription—DHFR—bone cancer	0.00127	0.0393	CbGpPWpGaD
Trimethoprim—TYMS—Nucleotide metabolism—NT5C3A—bone cancer	0.000923	0.0286	CbGpPWpGaD
Trimethoprim—TYMS—One Carbon Metabolism—DHFR—bone cancer	0.000851	0.0264	CbGpPWpGaD
Trimethoprim—TYMS—Trans-sulfuration and one carbon metabolism—DHFR—bone cancer	0.000765	0.0237	CbGpPWpGaD
Trimethoprim—TYMS—Fluoropyrimidine Activity—DHFR—bone cancer	0.000746	0.0231	CbGpPWpGaD
Trimethoprim—TYMS—E2F mediated regulation of DNA replication—DHFR—bone cancer	0.000746	0.0231	CbGpPWpGaD
Trimethoprim—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000693	0.0215	CbGpPWpGaD
Trimethoprim—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000662	0.0205	CbGpPWpGaD
Trimethoprim—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000606	0.0188	CbGpPWpGaD
Trimethoprim—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000568	0.0176	CbGpPWpGaD
Trimethoprim—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000567	0.0176	CbGpPWpGaD
Trimethoprim—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000564	0.0175	CbGpPWpGaD
Trimethoprim—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000539	0.0167	CbGpPWpGaD
Trimethoprim—TYMS—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000485	0.015	CbGpPWpGaD
Trimethoprim—TYMS—E2F transcription factor network—DHFR—bone cancer	0.000395	0.0123	CbGpPWpGaD
Trimethoprim—DHFR—E2F mediated regulation of DNA replication—RB1—bone cancer	0.000391	0.0121	CbGpPWpGaD
Trimethoprim—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000372	0.0115	CbGpPWpGaD
Trimethoprim—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00035	0.0108	CbGpPWpGaD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.000344	0.0106	CbGpPWpGaD
Trimethoprim—TYMS—E2F mediated regulation of DNA replication—RB1—bone cancer	0.000341	0.0106	CbGpPWpGaD
Trimethoprim—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000334	0.0104	CbGpPWpGaD
Trimethoprim—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000332	0.0103	CbGpPWpGaD
Trimethoprim—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000326	0.0101	CbGpPWpGaD
Trimethoprim—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000321	0.00996	CbGpPWpGaD
Trimethoprim—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000305	0.00944	CbGpPWpGaD
Trimethoprim—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000298	0.00924	CbGpPWpGaD
Trimethoprim—TYMS—G1/S Transition—DHFR—bone cancer	0.000287	0.00889	CbGpPWpGaD
Trimethoprim—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000272	0.00843	CbGpPWpGaD
Trimethoprim—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000262	0.00811	CbGpPWpGaD
Trimethoprim—DHFR—E2F transcription factor network—PLAU—bone cancer	0.000252	0.0078	CbGpPWpGaD
Trimethoprim—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000243	0.00752	CbGpPWpGaD
Trimethoprim—TYMS—Mitotic G1-G1/S phases—DHFR—bone cancer	0.000242	0.00749	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—ZW10—bone cancer	0.000239	0.00739	CbGpPWpGaD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00022	0.00682	CbGpPWpGaD
Trimethoprim—TYMS—E2F transcription factor network—PLAU—bone cancer	0.00022	0.00681	CbGpPWpGaD
Trimethoprim—Aplastic anaemia—Epirubicin—bone cancer	0.00022	0.00507	CcSEcCtD
Trimethoprim—Eye disorder—Cisplatin—bone cancer	0.000214	0.00493	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle—ZW10—bone cancer	0.000213	0.00661	CbGpPWpGaD
Trimethoprim—Tinnitus—Cisplatin—bone cancer	0.000213	0.00492	CcSEcCtD
Trimethoprim—Hyperkalaemia—Doxorubicin—bone cancer	0.000213	0.00491	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle, Mitotic—ZW10—bone cancer	0.000208	0.00645	CbGpPWpGaD
Trimethoprim—DHFR—E2F transcription factor network—RB1—bone cancer	0.000207	0.00641	CbGpPWpGaD
Trimethoprim—DHFR—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000207	0.00641	CbGpPWpGaD
Trimethoprim—Photosensitivity—Methotrexate—bone cancer	0.000207	0.00477	CcSEcCtD
Trimethoprim—Immune system disorder—Cisplatin—bone cancer	0.000207	0.00477	CcSEcCtD
Trimethoprim—Mediastinal disorder—Cisplatin—bone cancer	0.000206	0.00476	CcSEcCtD
Trimethoprim—Aplastic anaemia—Doxorubicin—bone cancer	0.000203	0.00469	CcSEcCtD
Trimethoprim—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000201	0.00622	CbGpPWpGaD
Trimethoprim—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.0002	0.0062	CbGpPWpGaD
Trimethoprim—Malnutrition—Cisplatin—bone cancer	0.000199	0.0046	CcSEcCtD
Trimethoprim—Erythema—Cisplatin—bone cancer	0.000199	0.0046	CcSEcCtD
Trimethoprim—Photosensitivity—Epirubicin—bone cancer	0.000193	0.00446	CcSEcCtD
Trimethoprim—Dermatitis exfoliative—Methotrexate—bone cancer	0.000192	0.00444	CcSEcCtD
Trimethoprim—DHFR—Fluoropyrimidine Activity—TP53—bone cancer	0.000191	0.00592	CbGpPWpGaD
Trimethoprim—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00019	0.0059	CbGpPWpGaD
Trimethoprim—Vascular purpura—Epirubicin—bone cancer	0.00019	0.00438	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000187	0.0058	CbGpPWpGaD
Trimethoprim—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000187	0.00579	CbGpPWpGaD
Trimethoprim—Tremor—Cisplatin—bone cancer	0.000187	0.00431	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—ZW10—bone cancer	0.000186	0.00577	CbGpPWpGaD
Trimethoprim—Lethargy—Methotrexate—bone cancer	0.000185	0.00427	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000181	0.0056	CbGpPWpGaD
Trimethoprim—TYMS—E2F transcription factor network—RB1—bone cancer	0.000181	0.0056	CbGpPWpGaD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.00018	0.00559	CbGpPWpGaD
Trimethoprim—Dermatitis exfoliative—Epirubicin—bone cancer	0.00018	0.00415	CcSEcCtD
Trimethoprim—DHFR—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.00018	0.00557	CbGpPWpGaD
Trimethoprim—Photosensitivity—Doxorubicin—bone cancer	0.000179	0.00413	CcSEcCtD
Trimethoprim—Renal impairment—Epirubicin—bone cancer	0.000178	0.00412	CcSEcCtD
Trimethoprim—Leukopenia—Cisplatin—bone cancer	0.000178	0.00411	CcSEcCtD
Trimethoprim—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000178	0.00551	CbGpPWpGaD
Trimethoprim—Dermatitis bullous—Epirubicin—bone cancer	0.000178	0.0041	CcSEcCtD
Trimethoprim—Purpura—Epirubicin—bone cancer	0.000176	0.00407	CcSEcCtD
Trimethoprim—Vascular purpura—Doxorubicin—bone cancer	0.000176	0.00405	CcSEcCtD
Trimethoprim—Hypoglycaemia—Epirubicin—bone cancer	0.000174	0.00402	CcSEcCtD
Trimethoprim—Lethargy—Epirubicin—bone cancer	0.000173	0.004	CcSEcCtD
Trimethoprim—Convulsion—Cisplatin—bone cancer	0.000172	0.00398	CcSEcCtD
Trimethoprim—Ataxia—Methotrexate—bone cancer	0.000171	0.00394	CcSEcCtD
Trimethoprim—Hyponatraemia—Epirubicin—bone cancer	0.00017	0.00393	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00017	0.00528	CbGpPWpGaD
Trimethoprim—Myalgia—Cisplatin—bone cancer	0.000169	0.00391	CcSEcCtD
Trimethoprim—Anxiety—Cisplatin—bone cancer	0.000169	0.0039	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000168	0.00389	CcSEcCtD
Trimethoprim—TYMS—Fluoropyrimidine Activity—TP53—bone cancer	0.000167	0.00517	CbGpPWpGaD
Trimethoprim—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000166	0.00384	CcSEcCtD
Trimethoprim—Renal impairment—Doxorubicin—bone cancer	0.000165	0.00381	CcSEcCtD
Trimethoprim—Dermatitis bullous—Doxorubicin—bone cancer	0.000164	0.00379	CcSEcCtD
Trimethoprim—TYMS—Circadian rythm related genes—GNA11—bone cancer	0.000164	0.00509	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—RFC1—bone cancer	0.000164	0.00508	CbGpPWpGaD
Trimethoprim—TYMS—Circadian rythm related genes—EZH2—bone cancer	0.000164	0.00507	CbGpPWpGaD
Trimethoprim—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000163	0.00377	CcSEcCtD
Trimethoprim—Purpura—Doxorubicin—bone cancer	0.000163	0.00376	CcSEcCtD
Trimethoprim—Anaphylactic shock—Cisplatin—bone cancer	0.000162	0.00375	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle—TUBB4B—bone cancer	0.000162	0.00501	CbGpPWpGaD
Trimethoprim—Hypoglycaemia—Doxorubicin—bone cancer	0.000161	0.00372	CcSEcCtD
Trimethoprim—Lethargy—Doxorubicin—bone cancer	0.00016	0.0037	CcSEcCtD
Trimethoprim—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00016	0.00496	CbGpPWpGaD
Trimethoprim—Ataxia—Epirubicin—bone cancer	0.00016	0.00368	CcSEcCtD
Trimethoprim—Nervous system disorder—Cisplatin—bone cancer	0.000159	0.00368	CcSEcCtD
Trimethoprim—Thrombocytopenia—Cisplatin—bone cancer	0.000159	0.00367	CcSEcCtD
Trimethoprim—Skin disorder—Cisplatin—bone cancer	0.000158	0.00364	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000158	0.00489	CbGpPWpGaD
Trimethoprim—Hyponatraemia—Doxorubicin—bone cancer	0.000158	0.00364	CcSEcCtD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000157	0.00486	CbGpPWpGaD
Trimethoprim—Eosinophilia—Methotrexate—bone cancer	0.000155	0.00358	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000155	0.00481	CbGpPWpGaD
Trimethoprim—Anorexia—Cisplatin—bone cancer	0.000155	0.00358	CcSEcCtD
Trimethoprim—Pancreatitis—Methotrexate—bone cancer	0.000154	0.00355	CcSEcCtD
Trimethoprim—DHFR—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000153	0.00475	CbGpPWpGaD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000153	0.00474	CbGpPWpGaD
Trimethoprim—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000153	0.00353	CcSEcCtD
Trimethoprim—DHFR—G1/S Transition—RB1—bone cancer	0.00015	0.00465	CbGpPWpGaD
Trimethoprim—Pancytopenia—Methotrexate—bone cancer	0.000149	0.00344	CcSEcCtD
Trimethoprim—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000148	0.00342	CcSEcCtD
Trimethoprim—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.000148	0.00458	CbGpPWpGaD
Trimethoprim—Ataxia—Doxorubicin—bone cancer	0.000148	0.00341	CcSEcCtD
Trimethoprim—Neutropenia—Methotrexate—bone cancer	0.000147	0.00338	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle—RFC1—bone cancer	0.000147	0.00454	CbGpPWpGaD
Trimethoprim—DHFR—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000146	0.00451	CbGpPWpGaD
Trimethoprim—Eosinophilia—Epirubicin—bone cancer	0.000145	0.00335	CcSEcCtD
Trimethoprim—Dyspnoea—Cisplatin—bone cancer	0.000145	0.00334	CcSEcCtD
Trimethoprim—Pancreatitis—Epirubicin—bone cancer	0.000144	0.00332	CcSEcCtD
Trimethoprim—Photosensitivity reaction—Methotrexate—bone cancer	0.000143	0.0033	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle, Mitotic—RFC1—bone cancer	0.000143	0.00443	CbGpPWpGaD
Trimethoprim—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000141	0.00327	CcSEcCtD
Trimethoprim—Decreased appetite—Cisplatin—bone cancer	0.000141	0.00326	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—TUBB4B—bone cancer	0.000141	0.00437	CbGpPWpGaD
Trimethoprim—Pneumonia—Methotrexate—bone cancer	0.000141	0.00325	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Cisplatin—bone cancer	0.00014	0.00324	CcSEcCtD
Trimethoprim—Infestation NOS—Methotrexate—bone cancer	0.00014	0.00323	CcSEcCtD
Trimethoprim—Infestation—Methotrexate—bone cancer	0.00014	0.00323	CcSEcCtD
Trimethoprim—Depression—Methotrexate—bone cancer	0.000139	0.00322	CcSEcCtD
Trimethoprim—Pancytopenia—Epirubicin—bone cancer	0.000139	0.00322	CcSEcCtD
Trimethoprim—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000139	0.0043	CbGpPWpGaD
Trimethoprim—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000139	0.0032	CcSEcCtD
Trimethoprim—Renal failure—Methotrexate—bone cancer	0.000137	0.00317	CcSEcCtD
Trimethoprim—Neutropenia—Epirubicin—bone cancer	0.000137	0.00317	CcSEcCtD
Trimethoprim—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000137	0.00424	CbGpPWpGaD
Trimethoprim—Stomatitis—Methotrexate—bone cancer	0.000136	0.00315	CcSEcCtD
Trimethoprim—Eosinophilia—Doxorubicin—bone cancer	0.000134	0.0031	CcSEcCtD
Trimethoprim—Photosensitivity reaction—Epirubicin—bone cancer	0.000134	0.00309	CcSEcCtD
Trimethoprim—Feeling abnormal—Cisplatin—bone cancer	0.000134	0.00309	CcSEcCtD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000134	0.00415	CbGpPWpGaD
Trimethoprim—Haematuria—Methotrexate—bone cancer	0.000133	0.00308	CcSEcCtD
Trimethoprim—Pancreatitis—Doxorubicin—bone cancer	0.000133	0.00307	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Methotrexate—bone cancer	0.000132	0.00305	CcSEcCtD
Trimethoprim—Epistaxis—Methotrexate—bone cancer	0.000132	0.00304	CcSEcCtD
Trimethoprim—Pneumonia—Epirubicin—bone cancer	0.000132	0.00304	CcSEcCtD
Trimethoprim—TYMS—G1/S Transition—RB1—bone cancer	0.000131	0.00406	CbGpPWpGaD
Trimethoprim—Infestation NOS—Epirubicin—bone cancer	0.000131	0.00302	CcSEcCtD
Trimethoprim—Infestation—Epirubicin—bone cancer	0.000131	0.00302	CcSEcCtD
Trimethoprim—Agranulocytosis—Methotrexate—bone cancer	0.00013	0.00301	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00013	0.00402	CbGpPWpGaD
Trimethoprim—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00013	0.00299	CcSEcCtD
Trimethoprim—Pancytopenia—Doxorubicin—bone cancer	0.000129	0.00298	CcSEcCtD
Trimethoprim—Renal failure—Epirubicin—bone cancer	0.000129	0.00297	CcSEcCtD
Trimethoprim—Body temperature increased—Cisplatin—bone cancer	0.000128	0.00296	CcSEcCtD
Trimethoprim—Neuropathy peripheral—Epirubicin—bone cancer	0.000128	0.00296	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—RFC1—bone cancer	0.000128	0.00396	CbGpPWpGaD
Trimethoprim—Stomatitis—Epirubicin—bone cancer	0.000128	0.00294	CcSEcCtD
Trimethoprim—TYMS—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000127	0.00394	CbGpPWpGaD
Trimethoprim—Neutropenia—Doxorubicin—bone cancer	0.000127	0.00293	CcSEcCtD
Trimethoprim—DHFR—Mitotic G1-G1/S phases—RB1—bone cancer	0.000127	0.00392	CbGpPWpGaD
Trimethoprim—Haematuria—Epirubicin—bone cancer	0.000125	0.00288	CcSEcCtD
Trimethoprim—Urinary tract disorder—Methotrexate—bone cancer	0.000124	0.00286	CcSEcCtD
Trimethoprim—Photosensitivity reaction—Doxorubicin—bone cancer	0.000124	0.00286	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Epirubicin—bone cancer	0.000124	0.00286	CcSEcCtD
Trimethoprim—Epistaxis—Epirubicin—bone cancer	0.000123	0.00285	CcSEcCtD
Trimethoprim—Urethral disorder—Methotrexate—bone cancer	0.000123	0.00284	CcSEcCtD
Trimethoprim—Agranulocytosis—Epirubicin—bone cancer	0.000122	0.00282	CcSEcCtD
Trimethoprim—Pneumonia—Doxorubicin—bone cancer	0.000122	0.00281	CcSEcCtD
Trimethoprim—Infestation NOS—Doxorubicin—bone cancer	0.000121	0.00279	CcSEcCtD
Trimethoprim—Infestation—Doxorubicin—bone cancer	0.000121	0.00279	CcSEcCtD
Trimethoprim—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00012	0.00277	CcSEcCtD
Trimethoprim—Hypersensitivity—Cisplatin—bone cancer	0.00012	0.00276	CcSEcCtD
Trimethoprim—Renal failure—Doxorubicin—bone cancer	0.000119	0.00275	CcSEcCtD
Trimethoprim—Erythema multiforme—Methotrexate—bone cancer	0.000119	0.00274	CcSEcCtD
Trimethoprim—Neuropathy peripheral—Doxorubicin—bone cancer	0.000119	0.00274	CcSEcCtD
Trimethoprim—Stomatitis—Doxorubicin—bone cancer	0.000118	0.00272	CcSEcCtD
Trimethoprim—Eye disorder—Methotrexate—bone cancer	0.000117	0.00271	CcSEcCtD
Trimethoprim—Tinnitus—Methotrexate—bone cancer	0.000117	0.0027	CcSEcCtD
Trimethoprim—Urinary tract disorder—Epirubicin—bone cancer	0.000116	0.00268	CcSEcCtD
Trimethoprim—DHFR—Metabolism—NDUFA12—bone cancer	0.000116	0.00359	CbGpPWpGaD
Trimethoprim—Haematuria—Doxorubicin—bone cancer	0.000115	0.00266	CcSEcCtD
Trimethoprim—Connective tissue disorder—Epirubicin—bone cancer	0.000115	0.00266	CcSEcCtD
Trimethoprim—Urethral disorder—Epirubicin—bone cancer	0.000115	0.00266	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Doxorubicin—bone cancer	0.000114	0.00264	CcSEcCtD
Trimethoprim—Epistaxis—Doxorubicin—bone cancer	0.000114	0.00264	CcSEcCtD
Trimethoprim—Immune system disorder—Methotrexate—bone cancer	0.000113	0.00262	CcSEcCtD
Trimethoprim—Mediastinal disorder—Methotrexate—bone cancer	0.000113	0.00261	CcSEcCtD
Trimethoprim—Agranulocytosis—Doxorubicin—bone cancer	0.000113	0.00261	CcSEcCtD
Trimethoprim—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000113	0.0035	CbGpPWpGaD
Trimethoprim—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000113	0.00349	CbGpPWpGaD
Trimethoprim—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000111	0.00345	CbGpPWpGaD
Trimethoprim—Diarrhoea—Cisplatin—bone cancer	0.000111	0.00257	CcSEcCtD
Trimethoprim—Erythema multiforme—Epirubicin—bone cancer	0.000111	0.00256	CcSEcCtD
Trimethoprim—TYMS—Mitotic G1-G1/S phases—RB1—bone cancer	0.00011	0.00342	CbGpPWpGaD
Trimethoprim—Mental disorder—Methotrexate—bone cancer	0.00011	0.00254	CcSEcCtD
Trimethoprim—Eye disorder—Epirubicin—bone cancer	0.00011	0.00253	CcSEcCtD
Trimethoprim—DHFR—Folate Metabolism—TP53—bone cancer	0.00011	0.0034	CbGpPWpGaD
Trimethoprim—Tinnitus—Epirubicin—bone cancer	0.00011	0.00253	CcSEcCtD
Trimethoprim—Malnutrition—Methotrexate—bone cancer	0.000109	0.00252	CcSEcCtD
Trimethoprim—Erythema—Methotrexate—bone cancer	0.000109	0.00252	CcSEcCtD
Trimethoprim—Urinary tract disorder—Doxorubicin—bone cancer	0.000107	0.00248	CcSEcCtD
Trimethoprim—Connective tissue disorder—Doxorubicin—bone cancer	0.000107	0.00247	CcSEcCtD
Trimethoprim—Urethral disorder—Doxorubicin—bone cancer	0.000107	0.00246	CcSEcCtD
Trimethoprim—Immune system disorder—Epirubicin—bone cancer	0.000106	0.00245	CcSEcCtD
Trimethoprim—Mediastinal disorder—Epirubicin—bone cancer	0.000106	0.00244	CcSEcCtD
Trimethoprim—Vomiting—Cisplatin—bone cancer	0.000103	0.00238	CcSEcCtD
Trimethoprim—Mental disorder—Epirubicin—bone cancer	0.000103	0.00238	CcSEcCtD
Trimethoprim—Erythema multiforme—Doxorubicin—bone cancer	0.000103	0.00237	CcSEcCtD
Trimethoprim—Rash—Cisplatin—bone cancer	0.000102	0.00236	CcSEcCtD
Trimethoprim—Dermatitis—Cisplatin—bone cancer	0.000102	0.00236	CcSEcCtD
Trimethoprim—Malnutrition—Epirubicin—bone cancer	0.000102	0.00236	CcSEcCtD
Trimethoprim—Erythema—Epirubicin—bone cancer	0.000102	0.00236	CcSEcCtD
Trimethoprim—Eye disorder—Doxorubicin—bone cancer	0.000102	0.00234	CcSEcCtD
Trimethoprim—Tinnitus—Doxorubicin—bone cancer	0.000101	0.00234	CcSEcCtD
Trimethoprim—TYMS—Metabolism—NDUFA12—bone cancer	0.000101	0.00313	CbGpPWpGaD
Trimethoprim—Immune system disorder—Doxorubicin—bone cancer	9.82e-05	0.00227	CcSEcCtD
Trimethoprim—Vertigo—Methotrexate—bone cancer	9.82e-05	0.00227	CcSEcCtD
Trimethoprim—Mediastinal disorder—Doxorubicin—bone cancer	9.79e-05	0.00226	CcSEcCtD
Trimethoprim—Leukopenia—Methotrexate—bone cancer	9.78e-05	0.00226	CcSEcCtD
Trimethoprim—Nausea—Cisplatin—bone cancer	9.65e-05	0.00223	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	9.62e-05	0.00298	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—NT5C3A—bone cancer	9.61e-05	0.00298	CbGpPWpGaD
Trimethoprim—Cough—Methotrexate—bone cancer	9.53e-05	0.0022	CcSEcCtD
Trimethoprim—Mental disorder—Doxorubicin—bone cancer	9.52e-05	0.0022	CcSEcCtD
Trimethoprim—Convulsion—Methotrexate—bone cancer	9.47e-05	0.00219	CcSEcCtD
Trimethoprim—Erythema—Doxorubicin—bone cancer	9.46e-05	0.00218	CcSEcCtD
Trimethoprim—Malnutrition—Doxorubicin—bone cancer	9.46e-05	0.00218	CcSEcCtD
Trimethoprim—Agitation—Epirubicin—bone cancer	9.4e-05	0.00217	CcSEcCtD
Trimethoprim—Arthralgia—Methotrexate—bone cancer	9.3e-05	0.00215	CcSEcCtD
Trimethoprim—Myalgia—Methotrexate—bone cancer	9.3e-05	0.00215	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.24e-05	0.00213	CcSEcCtD
Trimethoprim—TYMS—Circadian rythm related genes—CDK4—bone cancer	9.24e-05	0.00286	CbGpPWpGaD
Trimethoprim—Vertigo—Epirubicin—bone cancer	9.19e-05	0.00212	CcSEcCtD
Trimethoprim—Syncope—Epirubicin—bone cancer	9.17e-05	0.00212	CcSEcCtD
Trimethoprim—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.16e-05	0.00284	CbGpPWpGaD
Trimethoprim—Leukopenia—Epirubicin—bone cancer	9.15e-05	0.00211	CcSEcCtD
Trimethoprim—Confusional state—Methotrexate—bone cancer	8.99e-05	0.00208	CcSEcCtD
Trimethoprim—Loss of consciousness—Epirubicin—bone cancer	8.99e-05	0.00207	CcSEcCtD
Trimethoprim—Cough—Epirubicin—bone cancer	8.92e-05	0.00206	CcSEcCtD
Trimethoprim—Anaphylactic shock—Methotrexate—bone cancer	8.92e-05	0.00206	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle, Mitotic—DHFR—bone cancer	8.87e-05	0.00275	CbGpPWpGaD
Trimethoprim—Convulsion—Epirubicin—bone cancer	8.86e-05	0.00204	CcSEcCtD
Trimethoprim—DHFR—Retinoblastoma (RB) in Cancer—TP53—bone cancer	8.8e-05	0.00273	CbGpPWpGaD
Trimethoprim—Nervous system disorder—Methotrexate—bone cancer	8.74e-05	0.00202	CcSEcCtD
Trimethoprim—Thrombocytopenia—Methotrexate—bone cancer	8.73e-05	0.00202	CcSEcCtD
Trimethoprim—Arthralgia—Epirubicin—bone cancer	8.7e-05	0.00201	CcSEcCtD
Trimethoprim—Myalgia—Epirubicin—bone cancer	8.7e-05	0.00201	CcSEcCtD
Trimethoprim—Agitation—Doxorubicin—bone cancer	8.69e-05	0.00201	CcSEcCtD
Trimethoprim—Anxiety—Epirubicin—bone cancer	8.67e-05	0.002	CcSEcCtD
Trimethoprim—Skin disorder—Methotrexate—bone cancer	8.66e-05	0.002	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	8.64e-05	0.002	CcSEcCtD
Trimethoprim—Vertigo—Doxorubicin—bone cancer	8.5e-05	0.00196	CcSEcCtD
Trimethoprim—Anorexia—Methotrexate—bone cancer	8.5e-05	0.00196	CcSEcCtD
Trimethoprim—Syncope—Doxorubicin—bone cancer	8.48e-05	0.00196	CcSEcCtD
Trimethoprim—Leukopenia—Doxorubicin—bone cancer	8.47e-05	0.00195	CcSEcCtD
Trimethoprim—Confusional state—Epirubicin—bone cancer	8.41e-05	0.00194	CcSEcCtD
Trimethoprim—TYMS—Metabolism—NT5C3A—bone cancer	8.38e-05	0.0026	CbGpPWpGaD
Trimethoprim—Anaphylactic shock—Epirubicin—bone cancer	8.34e-05	0.00193	CcSEcCtD
Trimethoprim—Loss of consciousness—Doxorubicin—bone cancer	8.31e-05	0.00192	CcSEcCtD
Trimethoprim—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	8.3e-05	0.00257	CbGpPWpGaD
Trimethoprim—Cough—Doxorubicin—bone cancer	8.26e-05	0.00191	CcSEcCtD
Trimethoprim—Shock—Epirubicin—bone cancer	8.21e-05	0.00189	CcSEcCtD
Trimethoprim—Convulsion—Doxorubicin—bone cancer	8.2e-05	0.00189	CcSEcCtD
Trimethoprim—Nervous system disorder—Epirubicin—bone cancer	8.18e-05	0.00189	CcSEcCtD
Trimethoprim—Thrombocytopenia—Epirubicin—bone cancer	8.17e-05	0.00189	CcSEcCtD
Trimethoprim—Musculoskeletal discomfort—Methotrexate—bone cancer	8.12e-05	0.00188	CcSEcCtD
Trimethoprim—Skin disorder—Epirubicin—bone cancer	8.1e-05	0.00187	CcSEcCtD
Trimethoprim—Insomnia—Methotrexate—bone cancer	8.06e-05	0.00186	CcSEcCtD
Trimethoprim—Arthralgia—Doxorubicin—bone cancer	8.05e-05	0.00186	CcSEcCtD
Trimethoprim—Myalgia—Doxorubicin—bone cancer	8.05e-05	0.00186	CcSEcCtD
Trimethoprim—Anxiety—Doxorubicin—bone cancer	8.03e-05	0.00185	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	8e-05	0.00185	CcSEcCtD
Trimethoprim—Anorexia—Epirubicin—bone cancer	7.95e-05	0.00184	CcSEcCtD
Trimethoprim—Dyspnoea—Methotrexate—bone cancer	7.95e-05	0.00183	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—DHFR—bone cancer	7.93e-05	0.00246	CbGpPWpGaD
Trimethoprim—Dyspepsia—Methotrexate—bone cancer	7.85e-05	0.00181	CcSEcCtD
Trimethoprim—Confusional state—Doxorubicin—bone cancer	7.78e-05	0.0018	CcSEcCtD
Trimethoprim—Decreased appetite—Methotrexate—bone cancer	7.75e-05	0.00179	CcSEcCtD
Trimethoprim—Anaphylactic shock—Doxorubicin—bone cancer	7.72e-05	0.00178	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Methotrexate—bone cancer	7.7e-05	0.00178	CcSEcCtD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—TP53—bone cancer	7.68e-05	0.00238	CbGpPWpGaD
Trimethoprim—Musculoskeletal discomfort—Epirubicin—bone cancer	7.6e-05	0.00175	CcSEcCtD
Trimethoprim—Shock—Doxorubicin—bone cancer	7.6e-05	0.00175	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle—CHEK2—bone cancer	7.59e-05	0.00235	CbGpPWpGaD
Trimethoprim—Nervous system disorder—Doxorubicin—bone cancer	7.57e-05	0.00175	CcSEcCtD
Trimethoprim—Thrombocytopenia—Doxorubicin—bone cancer	7.56e-05	0.00174	CcSEcCtD
Trimethoprim—Insomnia—Epirubicin—bone cancer	7.55e-05	0.00174	CcSEcCtD
Trimethoprim—Skin disorder—Doxorubicin—bone cancer	7.5e-05	0.00173	CcSEcCtD
Trimethoprim—Dyspnoea—Epirubicin—bone cancer	7.44e-05	0.00172	CcSEcCtD
Trimethoprim—Anorexia—Doxorubicin—bone cancer	7.36e-05	0.0017	CcSEcCtD
Trimethoprim—Feeling abnormal—Methotrexate—bone cancer	7.35e-05	0.0017	CcSEcCtD
Trimethoprim—Dyspepsia—Epirubicin—bone cancer	7.35e-05	0.0017	CcSEcCtD
Trimethoprim—Gastrointestinal pain—Methotrexate—bone cancer	7.29e-05	0.00168	CcSEcCtD
Trimethoprim—Decreased appetite—Epirubicin—bone cancer	7.25e-05	0.00167	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Epirubicin—bone cancer	7.2e-05	0.00166	CcSEcCtD
Trimethoprim—Constipation—Epirubicin—bone cancer	7.14e-05	0.00165	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	7.13e-05	0.00221	CbGpPWpGaD
Trimethoprim—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	7.12e-05	0.00221	CbGpPWpGaD
Trimethoprim—Urticaria—Methotrexate—bone cancer	7.08e-05	0.00164	CcSEcCtD
Trimethoprim—Body temperature increased—Methotrexate—bone cancer	7.05e-05	0.00163	CcSEcCtD
Trimethoprim—Abdominal pain—Methotrexate—bone cancer	7.05e-05	0.00163	CcSEcCtD
Trimethoprim—Musculoskeletal discomfort—Doxorubicin—bone cancer	7.03e-05	0.00162	CcSEcCtD
Trimethoprim—Insomnia—Doxorubicin—bone cancer	6.98e-05	0.00161	CcSEcCtD
Trimethoprim—Dyspnoea—Doxorubicin—bone cancer	6.88e-05	0.00159	CcSEcCtD
Trimethoprim—Feeling abnormal—Epirubicin—bone cancer	6.88e-05	0.00159	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.88e-05	0.00213	CbGpPWpGaD
Trimethoprim—Gastrointestinal pain—Epirubicin—bone cancer	6.82e-05	0.00158	CcSEcCtD
Trimethoprim—Dyspepsia—Doxorubicin—bone cancer	6.8e-05	0.00157	CcSEcCtD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	6.79e-05	0.0021	CbGpPWpGaD
Trimethoprim—Decreased appetite—Doxorubicin—bone cancer	6.71e-05	0.00155	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Doxorubicin—bone cancer	6.67e-05	0.00154	CcSEcCtD
Trimethoprim—Urticaria—Epirubicin—bone cancer	6.63e-05	0.00153	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—CHEK2—bone cancer	6.63e-05	0.00205	CbGpPWpGaD
Trimethoprim—Constipation—Doxorubicin—bone cancer	6.6e-05	0.00152	CcSEcCtD
Trimethoprim—Abdominal pain—Epirubicin—bone cancer	6.6e-05	0.00152	CcSEcCtD
Trimethoprim—Body temperature increased—Epirubicin—bone cancer	6.6e-05	0.00152	CcSEcCtD
Trimethoprim—Hypersensitivity—Methotrexate—bone cancer	6.57e-05	0.00152	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle—BRCA2—bone cancer	6.44e-05	0.00199	CbGpPWpGaD
Trimethoprim—Feeling abnormal—Doxorubicin—bone cancer	6.36e-05	0.00147	CcSEcCtD
Trimethoprim—Gastrointestinal pain—Doxorubicin—bone cancer	6.31e-05	0.00146	CcSEcCtD
Trimethoprim—Pruritus—Methotrexate—bone cancer	6.31e-05	0.00146	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	6.2e-05	0.00192	CbGpPWpGaD
Trimethoprim—Hypersensitivity—Epirubicin—bone cancer	6.15e-05	0.00142	CcSEcCtD
Trimethoprim—Urticaria—Doxorubicin—bone cancer	6.13e-05	0.00142	CcSEcCtD
Trimethoprim—Abdominal pain—Doxorubicin—bone cancer	6.1e-05	0.00141	CcSEcCtD
Trimethoprim—Body temperature increased—Doxorubicin—bone cancer	6.1e-05	0.00141	CcSEcCtD
Trimethoprim—Diarrhoea—Methotrexate—bone cancer	6.1e-05	0.00141	CcSEcCtD
Trimethoprim—CYP2C8—Biological oxidations—CYP3A4—bone cancer	5.98e-05	0.00185	CbGpPWpGaD
Trimethoprim—TYMS—Circadian rythm related genes—JUN—bone cancer	5.95e-05	0.00184	CbGpPWpGaD
Trimethoprim—Pruritus—Epirubicin—bone cancer	5.9e-05	0.00136	CcSEcCtD
Trimethoprim—Dizziness—Methotrexate—bone cancer	5.9e-05	0.00136	CcSEcCtD
Trimethoprim—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	5.89e-05	0.00183	CbGpPWpGaD
Trimethoprim—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	5.79e-05	0.00179	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.77e-05	0.00179	CbGpPWpGaD
Trimethoprim—Diarrhoea—Epirubicin—bone cancer	5.71e-05	0.00132	CcSEcCtD
Trimethoprim—Hypersensitivity—Doxorubicin—bone cancer	5.69e-05	0.00131	CcSEcCtD
Trimethoprim—Vomiting—Methotrexate—bone cancer	5.67e-05	0.00131	CcSEcCtD
Trimethoprim—Rash—Methotrexate—bone cancer	5.62e-05	0.0013	CcSEcCtD
Trimethoprim—Dermatitis—Methotrexate—bone cancer	5.62e-05	0.0013	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—BRCA2—bone cancer	5.62e-05	0.00174	CbGpPWpGaD
Trimethoprim—Headache—Methotrexate—bone cancer	5.59e-05	0.00129	CcSEcCtD
Trimethoprim—Dizziness—Epirubicin—bone cancer	5.52e-05	0.00127	CcSEcCtD
Trimethoprim—Pruritus—Doxorubicin—bone cancer	5.46e-05	0.00126	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle, Mitotic—CDK4—bone cancer	5.34e-05	0.00165	CbGpPWpGaD
Trimethoprim—Vomiting—Epirubicin—bone cancer	5.31e-05	0.00122	CcSEcCtD
Trimethoprim—Nausea—Methotrexate—bone cancer	5.3e-05	0.00122	CcSEcCtD
Trimethoprim—Diarrhoea—Doxorubicin—bone cancer	5.28e-05	0.00122	CcSEcCtD
Trimethoprim—Rash—Epirubicin—bone cancer	5.26e-05	0.00121	CcSEcCtD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.26e-05	0.00163	CbGpPWpGaD
Trimethoprim—Dermatitis—Epirubicin—bone cancer	5.26e-05	0.00121	CcSEcCtD
Trimethoprim—Headache—Epirubicin—bone cancer	5.23e-05	0.00121	CcSEcCtD
Trimethoprim—CYP2C8—Biological oxidations—GSTP1—bone cancer	5.11e-05	0.00158	CbGpPWpGaD
Trimethoprim—Dizziness—Doxorubicin—bone cancer	5.11e-05	0.00118	CcSEcCtD
Trimethoprim—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	5.04e-05	0.00156	CbGpPWpGaD
Trimethoprim—DHFR—Disease—ENO2—bone cancer	5.02e-05	0.00156	CbGpPWpGaD
Trimethoprim—Nausea—Epirubicin—bone cancer	4.96e-05	0.00114	CcSEcCtD
Trimethoprim—Vomiting—Doxorubicin—bone cancer	4.91e-05	0.00113	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.87e-05	0.00151	CbGpPWpGaD
Trimethoprim—Rash—Doxorubicin—bone cancer	4.87e-05	0.00112	CcSEcCtD
Trimethoprim—CYP2C9—Biological oxidations—CYP3A4—bone cancer	4.86e-05	0.00151	CbGpPWpGaD
Trimethoprim—Dermatitis—Doxorubicin—bone cancer	4.86e-05	0.00112	CcSEcCtD
Trimethoprim—Headache—Doxorubicin—bone cancer	4.84e-05	0.00112	CcSEcCtD
Trimethoprim—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	4.8e-05	0.00149	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.79e-05	0.00148	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—CDK4—bone cancer	4.77e-05	0.00148	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.72e-05	0.00146	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—CDK4—bone cancer	4.66e-05	0.00144	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—RB1—bone cancer	4.64e-05	0.00144	CbGpPWpGaD
Trimethoprim—Nausea—Doxorubicin—bone cancer	4.59e-05	0.00106	CcSEcCtD
Trimethoprim—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.48e-05	0.00139	CbGpPWpGaD
Trimethoprim—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.23e-05	0.00131	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—ENO2—bone cancer	4.21e-05	0.0013	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—CDK4—bone cancer	4.16e-05	0.00129	CbGpPWpGaD
Trimethoprim—CYP2C9—Biological oxidations—GSTP1—bone cancer	4.16e-05	0.00129	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—RB1—bone cancer	4.15e-05	0.00129	CbGpPWpGaD
Trimethoprim—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	4.1e-05	0.00127	CbGpPWpGaD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.09e-05	0.00127	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—RB1—bone cancer	4.05e-05	0.00126	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4e-05	0.00124	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.99e-05	0.00124	CbGpPWpGaD
Trimethoprim—TYMS—Circadian rythm related genes—TP53—bone cancer	3.93e-05	0.00122	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—ENO2—bone cancer	3.67e-05	0.00114	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—GNA11—bone cancer	3.65e-05	0.00113	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—RB1—bone cancer	3.62e-05	0.00112	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—NDUFA12—bone cancer	3.58e-05	0.00111	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—MDM2—bone cancer	3.54e-05	0.0011	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.45e-05	0.00107	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—DHFR—bone cancer	3.41e-05	0.00106	CbGpPWpGaD
Trimethoprim—DHFR—Disease—TGFBR2—bone cancer	3.38e-05	0.00105	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—CYP3A4—bone cancer	3.31e-05	0.00102	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—GNA11—bone cancer	3.18e-05	0.000986	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—NDUFA12—bone cancer	3.12e-05	0.000967	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—MDM2—bone cancer	3.09e-05	0.000957	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.97e-05	0.00092	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—NT5C3A—bone cancer	2.97e-05	0.00092	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—NDUFA12—bone cancer	2.92e-05	0.000904	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—CYP3A4—bone cancer	2.89e-05	0.000894	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—GSTP1—bone cancer	2.83e-05	0.000877	CbGpPWpGaD
Trimethoprim—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.74e-05	0.00085	CbGpPWpGaD
Trimethoprim—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.71e-05	0.000839	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—NT5C3A—bone cancer	2.59e-05	0.000801	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—GSTP1—bone cancer	2.47e-05	0.000765	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—NT5C3A—bone cancer	2.42e-05	0.000749	CbGpPWpGaD
Trimethoprim—DHFR—Disease—KIT—bone cancer	2.3e-05	0.000714	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.2e-05	0.000682	CbGpPWpGaD
Trimethoprim—DHFR—Disease—BRAF—bone cancer	2.17e-05	0.000671	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.12e-05	0.000657	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—TP53—bone cancer	2.03e-05	0.000629	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—NDUFA12—bone cancer	1.92e-05	0.000596	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.91e-05	0.000593	CbGpPWpGaD
Trimethoprim—DHFR—Disease—MDM2—bone cancer	1.82e-05	0.000563	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—TP53—bone cancer	1.77e-05	0.000549	CbGpPWpGaD
Trimethoprim—DHFR—Disease—PTGS2—bone cancer	1.75e-05	0.000542	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—NT5C3A—bone cancer	1.59e-05	0.000494	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.5e-05	0.000466	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—PTGS2—bone cancer	1.47e-05	0.000454	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—ENO2—bone cancer	1.3e-05	0.000403	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—PTGS2—bone cancer	1.28e-05	0.000396	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.26e-05	0.000391	CbGpPWpGaD
Trimethoprim—DHFR—Disease—EGFR—bone cancer	1.24e-05	0.000384	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—DHFR—bone cancer	1.21e-05	0.000374	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—ENO2—bone cancer	1.13e-05	0.000351	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—GNA11—bone cancer	1.13e-05	0.000349	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—ENO2—bone cancer	1.06e-05	0.000328	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—DHFR—bone cancer	1.05e-05	0.000326	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—CYP3A4—bone cancer	1.02e-05	0.000317	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.02e-05	0.000315	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—GNA11—bone cancer	9.82e-06	0.000304	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—DHFR—bone cancer	9.82e-06	0.000304	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—GNA11—bone cancer	9.18e-06	0.000284	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—CYP3A4—bone cancer	8.9e-06	0.000276	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—GSTP1—bone cancer	8.74e-06	0.000271	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—CYP3A4—bone cancer	8.32e-06	0.000258	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.28e-06	0.000256	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—GSTP1—bone cancer	7.62e-06	0.000236	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—GSTP1—bone cancer	7.11e-06	0.00022	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—ENO2—bone cancer	6.98e-06	0.000216	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—DHFR—bone cancer	6.47e-06	0.000201	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—GNA11—bone cancer	6.05e-06	0.000188	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—GSTP1—bone cancer	4.69e-06	0.000145	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PTGS2—bone cancer	4.53e-06	0.00014	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PTGS2—bone cancer	3.95e-06	0.000122	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PTGS2—bone cancer	3.69e-06	0.000114	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PTGS2—bone cancer	2.43e-06	7.53e-05	CbGpPWpGaD
